Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Rating of “Hold” from Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have earned an average recommendation of “Hold” from the fourteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $87.8462.

A number of brokerages recently commented on HSIC. Robert W. Baird set a $97.00 price target on Henry Schein in a research note on Wednesday, May 6th. UBS Group reissued a “neutral” rating and set a $85.00 price target (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Finally, Citigroup assumed coverage on Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target for the company.

Insider Activity

In related news, Director William K. Daniel acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $69.19 per share, with a total value of $691,900.00. Following the purchase, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.89% of the stock is owned by insiders.

Institutional Investors Weigh In On Henry Schein

Several institutional investors have recently modified their holdings of HSIC. CYBER HORNET ETFs LLC purchased a new stake in shares of Henry Schein in the second quarter worth approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter worth approximately $27,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Henry Schein in the fourth quarter worth approximately $30,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein in the fourth quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein in the fourth quarter worth approximately $37,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

NASDAQ HSIC opened at $84.95 on Friday. The firm has a market cap of $9.68 billion, a price-to-earnings ratio of 25.66, a price-to-earnings-growth ratio of 1.61 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $76.54 and a 200-day moving average price of $76.72. Henry Schein has a twelve month low of $61.94 and a twelve month high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the company earned $1.15 earnings per share. The firm’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts predict that Henry Schein will post 5.32 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.